RxDoctor Payments Data

Mary Buckwalter

Nurse Practitioner · Baton Rouge, LANPI 1013682012

Payments from drug & device makers

$3,245in general payments, 2019–2025

Across 183 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$571
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$370
  • Johnson & Johnson$328
  • Takeda Pharmaceuticals U.S.A., Inc.$298
  • Ardelyx, Inc.$241
  • Celltrion USA Inc.$170
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,245100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,245 in reported general payments places this provider in the 85th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$55,677
Medicare patients
316
Services billed
577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide83$72,005
IbsrelaTenapanor Hcl21$39,096
CreonLipase/Protease/Amylase14$34,743
Mesalamine18$13,760
MovantikNaloxegol Oxalate11$8,271
Pantoprazole Sodium619$6,850
Mesalamine ErMesalamine20$6,786
ClenpiqSod Picosulf/Mag Ox/Citric Ac24$3,821
DexilantDexlansoprazole13$3,772
Lubiprostone28$2,291
Sucralfate20$2,061
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C15$2,052
Esomeprazole Magnesium61$1,914
Omeprazole121$1,824
Colestipol Hcl22$1,542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$571$106,74897 claims
Ardelyx, Inc.Ibsrela$241$39,09621 claims
Redhill Biopharma Inc.Movantik$44$8,27111 claims
Ferring Pharmaceuticals Inc.Clenpiq$119$3,82124 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$298$3,77213 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$370$2,05215 claims
Braintree Laboratories, Inc.Suflave$55$1,43612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →